BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
New compound could one day help Bristol tap into a growing area of unmet need in diabetes.
You may also be interested in...
Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.
AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared
AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb is buying the biotech company Medarex in a deal valued at $2.4 billion, or $16.00 per share in cash, the companies announced July 22. In doing so, Bristol gains full rights to the late-stage cancer drug ipilimumab and to innovative technologies for developing immunology and oncology humanized antibodies